RxDoctor Payments Data

Lisa Tucker

Family · Columbia, SCNPI 1679093462

Payments from drug & device makers

$824in general payments, 2019–2025

Across 24 payments — averaging $34.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$174
  • Otsuka America Pharmaceutical, Inc.$139
  • Boehringer Ingelheim$139
  • Insulet Corporation$137
  • Xeris Pharmaceuticals, Inc.$58
  • Sanofi-aventis U.S. LLC$39
  • plus $137 from 8 others

What the payments were for

  • Food & beverage$76092%
  • Education$658%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$824 in reported general payments places this provider in the 60th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$51,976
Medicare patients
41
Services billed
756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin14$10,793
EliquisApixaban11$10,682
XareltoRivaroxaban11$6,634
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,063
Nano 2nd Gen Pen NeedlePen Needle, Diabetic16$1,300
Gabapentin41$907
Mirtazapine18$615
Pantoprazole Sodium39$601
Trazodone Hcl23$524
Atorvastatin Calcium51$448
Amiodarone Hcl14$386
Potassium Chloride18$350
Baclofen12$346
Amlodipine Besylate59$327
Metoprolol Succinate14$294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$139$10,79314 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$12611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →